hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2014.55.621

Antithrombotics in heart failure

Davor Miličić ; 1University of Zagreb Schoolof Medicine, Department forCardiovascular Diseases, UniversityHospital Center Zagreb, Zagreb,Croatia
Jure Samardžić ; 1University of Zagreb Schoolof Medicine, Department forCardiovascular Diseases, UniversityHospital Center Zagreb, Zagreb,Croatia
Mate Petričević ; Department for Cardiac Surgery, University Hospital Center Zagreb,Zagreb, Croatia

Puni tekst: engleski, pdf (135 KB) str. 621-627 preuzimanja: 351* citiraj
APA 6th Edition
Miličić, D., Samardžić, J. i Petričević, M. (2014). Antithrombotics in heart failure. Croatian Medical Journal, 55 (6), 621-627. https://doi.org/10.3325/cmj.2014.55.621
MLA 8th Edition
Miličić, Davor, et al. "Antithrombotics in heart failure." Croatian Medical Journal, vol. 55, br. 6, 2014, str. 621-627. https://doi.org/10.3325/cmj.2014.55.621. Citirano 27.10.2021.
Chicago 17th Edition
Miličić, Davor, Jure Samardžić i Mate Petričević. "Antithrombotics in heart failure." Croatian Medical Journal 55, br. 6 (2014): 621-627. https://doi.org/10.3325/cmj.2014.55.621
Harvard
Miličić, D., Samardžić, J., i Petričević, M. (2014). 'Antithrombotics in heart failure', Croatian Medical Journal, 55(6), str. 621-627. https://doi.org/10.3325/cmj.2014.55.621
Vancouver
Miličić D, Samardžić J, Petričević M. Antithrombotics in heart failure. Croat Med J. [Internet]. 2014 [pristupljeno 27.10.2021.];55(6):621-627. https://doi.org/10.3325/cmj.2014.55.621
IEEE
D. Miličić, J. Samardžić i M. Petričević, "Antithrombotics in heart failure", Croatian Medical Journal, vol.55, br. 6, str. 621-627, 2014. [Online]. https://doi.org/10.3325/cmj.2014.55.621

Sažetak
Heart failure is a common clinical condition associated with
high morbidity and mortality rate despite significant improvements
in pharmacotherapy and implementation of
medical procedures. Patients with heart failure are at an increased
risk of developing arterial and venous thrombosis,
which contribute to the high rate of adverse events and fatal
outcomes. Many heart failure patients routinely receive
antithrombotic therapy due to the presence of a specific
indication for its use, like ischemic heart disease or atrial
fibrillation. However, there is no solid evidence to support
the routine use of antithrombotic agents in all heart failure
patients. This article reviews the evidence for using antithrombotic
therapy in heart failure patients.

Hrčak ID: 139290

URI
https://hrcak.srce.hr/139290

Posjeta: 563 *